argenx vs Merck & stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
argenx is more profitable, grows faster and has less debt. Merck & is cheaper for its profits.
Side by side
| argenx | Merck & | |
|---|---|---|
| $58.2 billion | $330 billion | |
| 31.1% | 28.1% | |
| +116.2% | +9.4% | |
| 45.1× | 18.1× | |
| Net cash | 1.2 years | |
| 11.7% | 17.8% | |
| – | 2.8% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: argenx vs Roche · argenx vs UnitedHealth · argenx vs AbbVie · argenx vs Johnson & Johnson · Merck & vs Bayer · Merck & vs Gilead Sciences · Merck & vs Intuitive Surgical · Merck & vs Johnson & Johnson

